Clinical Trial Update: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies [Phase 1]

View source ↗

Summary

Poseida Therapeutics is conducting a Phase 1 trial of P-CD19CD20-ALLO1, an allogeneic CAR-T cell therapy, for several B-cell malignancies and is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Arising From Follicular Lymphoma
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• P-CD19CD20-ALLO1 Allogeneic CAR-T Cells

Snippet

Sponsor: Poseida Therapeutics, Inc. | Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Status: RECRUITING